PrE0807: Neoadjuvant nivolumab without or with lirilumab in cisplatin-ineligible...
Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA
22 Jun 2021
CheckMate067 outcomes: Nivolumab plus ipilimumab in advanced melanoma
Dr Jedd Wolchok - Memorial Sloan Kettering Center, New York, USA
9 Jun 2021
LEAP-004: Lenvatinib + pembrolizumab for patients with advanced melanoma and con...
Dr Ana Arance - Hospital Clínic de Barcelona, Barcelona, Spain
8 Jun 2021
Highlights from ASCO 2021
Dr Bishal Gyawali - Queen's University, Kingston, Canada
8 Jun 2021
OncoAlert and ecancer ASCO roundup - Day 3
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
8 Jun 2021
RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-lin...
Dr Evan Jacob Lipson - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, ...
4 Jun 2021
Phase III randomised trial comparing tebentafusp with investigator’s choice in f...
Dr Jessica Hassel - University Hospital Heidelberg, Heidelberg, Germany
16 Apr 2021
Adjuvant therapy with nivolumab combined with ipilimumab vs nivolumab alone in p...
Prof Georgina Long - University of Sydney, Sydney, Australia
13 Apr 2021
Autologous tumour infiltrating lymphocytes cell therapy in metastatic non-small ...
Dr Erminia Massarelli - City of Hope, Duarte, USA
1 Apr 2021
OncoAlert and ecancer weekly roundup for January 25 - 31, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
4 Feb 2021
Advances and challenges in treating melanoma and breast cancer in Romania
Dr Daniela Zob - Institute of Oncology, Bucharest, Romania
18 Jan 2021
OncoAlert Colloquium Day 4: Gynae-oncology, lymphoma, sarcoma and melanoma
Dr Dizon, Dr Trent, Dr Cordoba, Dr Rolfo, Dr Haanen
23 Dec 2020
